宫内膜干细胞治疗失代偿期肝硬化疗效观察

Endometrial stem cell treatment of decompensated liver cirrhosis

目的探讨宫内膜干细胞移植治疗失代偿期肝硬化的临床疗效。方法选择肝硬化失代偿期患者23例,宫内膜干细胞经静脉输注方法移植入肝脏,分别在治疗后第1周、2周、1个月、3个月、6个月、12个月复查肝脏功能(TBIL、ALT、AST)、甲胎蛋白(AFP)、胆碱酯酶(CHE)、肝纤维化等实验室指标,分析临床症状及不良反应情况。结果治疗后23例临床症状及体征明显改善。移植治疗后,在各观察点复查肝功能TBIL、ALT、AST、AFP较治疗前均降低,但差异无统计学意义;ALB(34.8 g/L)和CHE(4386 U/L)较治疗前显著升高,差异有统计学意义(P<0.05)。肝纤维化指标LN、HA、PC-Ⅲ、Ⅳ较治疗前均减少,差异有统计学意义(P<0.05)。结论宫内膜干细胞移植治疗可明显改善肝硬化失代偿期患者肝脏功能及临床症状,短期结果安全可靠,不良反应少,值得临床进一步研究。

Objective To study the efficacy of endometrial stem cell transplantation for patients with decompensated liver cirrhosis. Methods Patients with decompensated liver cirrhosis （n = 23 ） were recruited. Endometrial stem cells were transplanted into the liver by intravenous infusion. Some indexes were checked in one week after the treatment, 2 weeks, 1 month, 3 months, 6 months, 12 months, respectively; these indexes included liver function, AFP, cholinesterase, liver fibrosis index of laboratory, clinical symptoms and adverse reaction condition. Results The clinical symptoms and signs in most patients were improved significantly after treatment. Endometrial stem cell transplantation treatment decreased the liver function TBIL, ALT, AST, AFP compared with those before treatment, but the difference was not statistically significant; ALB and CHE were significantly higher than those before treatment, the difference was statistically significant （ P 〈 0.05）. Liver fibrosis indexes LN, HA, PC-Ⅲ, Ⅳ（ especially HA） were lower than before treatment, the difference was statistically significant （ P 〈 0.05 ）. Conclusions For endometrial stem cell transplantation in the treatment of patients with decompensated liver cirrhosis, their clinical symptoms were significantly improved, according to short-term observation, the therapy is safe and reliable, with less adverse reactions, it is worthy of further clinical research.